Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F*

The majority of the BCR-ABL-negative myeloproliferative disorders express the mutant JAK2, JAK2V617F. Previously we showed that constitutive activation of this oncogenic JAK2 mutant in Ba/F3 or 32D cells requires coexpression of a cognate homodimeric cytokine receptor, such as the EpoR. However, overexpression of JAK2V617F in Ba/F3 cells renders them cytokine-independent for growth in the absence of an exogenous cytokine receptor. Here, we demonstrated that JAK2V617F domains required for receptor association are essential for cytokine-independent growth by overexpressed JAK2V617F, suggesting JAK2V617F is binding to an unknown endogenous cytokine receptor(s) for its activation. We further showed that disruption of EpoR dimerization by coexpressing a truncated EpoR disrupted JAK2V617F-mediated transformation, indicating that EpoR dimerization plays an essential role in the activation of JAK2V617F. Interestingly, coexpression of JAK2V617F with EpoR mutants that retain JAK2 binding but are defective in mediating Epo-dependent JAK2 activation due to mutations in a conserved juxtamembrane motif does lead to cytokine-independent activation of JAK2V617F. Overall, these findings confirm that JAK2V617F requires binding to a dimerized cytokine receptor for its activation, and that the key EpoR juxtamembrane regulatory motif essential for Epo-dependent JAK2 activation is not essential for the activation of JAK2V617F. The structure of the activated JAK2V617F is thus likely to be different from that of the activated wild-type JAK2, raising the possibility of developing a specifically targeted therapy for myeloproliferative disorders.

• Publication year

  2008

• Venue

  Journal of Biological Chemistry

• Publication date

  2008-02-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1074/jbc.M707125200PMID 18158285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

  2007cited by this paper
• Jak2: normal function and role in hematopoietic disorders.

  2007cited by this paper
• Oncogenes in Myeloproliferative Disorders

  2007cited by this paper
• The JAK2 V617F mutation in de novo acute myelogenous leukemias

  2006cited by this paper
• Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2

  2006cited by this paper
• JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

  2006cited by this paper
• Characterization of murine JAK2V617F-positive myeloproliferative disease.

  2006cited by this paper
• Activating alleles of JAK3 in acute megakaryoblastic leukemia.

  2006cited by this paper
• JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.

  2005cited by this paper
• The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

  2005cited by this paper
• The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia

  2005cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• Normal and oncogenic FLT3.

  2004cited by this paper
• The Janus kinases (Jaks)

  2004cited by this paper
• Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.

  2001cited by this paper
• The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor.

  2001cited by this paper
• Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.

  2001cited by this paper
• The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.

  2001cited by this paper
• Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain

  2001cited by this paper
• Generation of mammalian cells stably expressing multiple genes at predetermined levels.

  2000cited by this paper
• Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain

  2000cited by this paper
• Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

  1998cited by this paper
• Efficiency of signalling through cytokine receptors depends critically on receptor orientation

  1998cited by this paper
• Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.

  1998cited by this paper
• A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.

  1997cited by this paper
• A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation

  1994cited by this paper

• JAK2/STAT3-dependent regulation of MDM4/MDM2-p53 signaling in methotrexate-induced ferroptosis and nephrotoxicity.

  2026cites this paper
• Delineating Mpl-dependent and -independent phenotypes of Jak2 V617F- positive MPNs in vivo.

  2025cites this paper
• The V617F mutation in JAK2 renders myeloid cells more sensitive to IL-6-mediated gp130 signaling

  2025cites this paper
• Recent advances and future perspectives in small molecule JAK2 inhibitors.

  2025cites this paper
• Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease

  2024cites this paper
• New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

  2024cites this paper
• Normal and dysregulated crosstalk between iron metabolism and erythropoiesis

  2023cites this paper
• Hepcidin and its multiple partners: Complex regulation of iron metabolism in health and disease.

  2023cites this paper
• Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms

  2022cites this paper
• Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis

  2022cites this paper
• Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.

  2022cites this paper
• JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

  2022cites this paper
• Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications

  2021cites this paper
• Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology

  2021cites this paper
• Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms

  2021cites this paper
• The JAK2 mutation.

  2021cites this paper
• MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations

  2021cites this paper
• HYDROXYCARBAMIDE EFFECT ON DNA METHYLATION AND GENE EXPRESSION IN MYELOPROLIFERATIVE NEOPLASMS: A CROSS-SPECIES STUDY

  2021cites this paper
• Functional Consequences of Mutations in Myeloproliferative Neoplasms

  2021cites this paper
• Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms

  2021cites this paper
• The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.

  2021cites this paper
• Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.

  2021cites this paper
• Murine Models of Myelofibrosis

  2020cites this paper
• Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations

  2020cites this paper
• OTT_A_287944 12367..12382

  2020cites this paper
• Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data

  2020cites this paper
• Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics

  2019cites this paper
• Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations

  2019cites this paper
• The regulation of JAKs in cytokine signaling and its breakdown in disease.

  2019cites this paper
• Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions

  2019cites this paper
• Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1

  2019influential citation
• The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications

  2019cites this paper
• Hepcidin-ferroportin axis in health and disease.

  2019cites this paper
• Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

  2019cites this paper
• Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

  2018cites this paper
• Emerging drugs for the treatment of Myelofibrosis

  2018cites this paper
• The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects

  2018cites this paper
• Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance

  2018cites this paper
• FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity

  2018cites this paper
• Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase

  2018cites this paper
• Dysregulated iron metabolism in polycythemia vera: etiology and consequences

  2018cites this paper
• Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression

  2018cites this paper
• JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders

  2018cites this paper
• Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?

  2017cites this paper
• 12 Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia

  2017cites this paper
• JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.

  2017cites this paper
• Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm

  2017cites this paper
• Die Bedeutung des multi-site docking Proteins Gab1 in der Epo-, Jak2-V617F- und IL-6-induzierten Signaltransduktion

  2017cites this paper
• Pharmacotherapy of Myelofibrosis

  2017cites this paper
• Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs)

  2017cites this paper
• Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition

  2017cites this paper
• Activating JAK 2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm

  2017cites this paper
• Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations

  2017cites this paper
• Pseudokinases: update on their functions and evaluation as new drug targets.

  2017cites this paper
• JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.

  2016cites this paper
• Noncanonical IFN Signaling: Mechanistic Linkage of Genetic and Epigenetic Events

  2016cites this paper
• Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.

  2016cites this paper
• MDM2 facilitates adipocyte differentiation through CRTC-mediated activation of STAT3

  2016cites this paper
• Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling

  2016cites this paper
• Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix

  2016cites this paper
• Rôle des cellules endothéliales JAK2V617F dans l’augmentation de l’angiogenèse des néoplasies myéloprolifératives.

  2015cites this paper
• Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.

  2015cites this paper
• Pediatric High Risk Leukemia — Molecular Insights

  2015influential citation
• ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation

  2015cites this paper
• Mechanisms of pre‐B‐cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia

  2015cites this paper
• JAK/STAT Signalling and Haematological Malignancies

  2015cites this paper
• JAK2 activation by growth hormone and other cytokines

  2015cites this paper
• Hematopoietic Cells c-Abl Activates Janus Kinase 2 in Normal

  2014cites this paper
• Eliminative Signaling by Janus Kinases: Role in the Downregulation of Associated Receptors

  2014cites this paper
• Hormone Receptor Mechanism of Activation of Protein Kinase JAK 2 by the Growth

  2014cites this paper
• Myeloproliferative Neoplasms - Molecular Biology and Potential Targets for Intervention

  2014cites this paper
• Functional Characterization of the Kinase and Pseudokinase Domains in the Janus Tyrosine Kinase (JAK) 2

  2014cites this paper
• How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

  2014cites this paper
• Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms.

  2014cites this paper
• The molecular regulation of Janus kinase (JAK) activation.

  2014cites this paper
• c-Abl Activates Janus Kinase 2 in Normal Hematopoietic Cells*

  2014cites this paper
• A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors

  2014cites this paper
• Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor

  2014cites this paper
• Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

  2014cites this paper
• IFN Signaling: How a Non-Canonical Model Led to the Development of IFN Mimetics

  2013cites this paper
• The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis

  2013cites this paper
• Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.

  2013cites this paper
• Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors

  2013cites this paper
• JAK2‐V617F‐mediated signalling is dependent on lipid rafts and statins inhibit JAK2‐V617F‐dependent cell growth

  2013influential citation
• Lymphoid malignancies: Another face to the Janus kinases.

  2013cites this paper
• JAK/STAT signaling in hematological malignancies

  2013cites this paper
• Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

  2013cites this paper
• Antagonistic activities of the immunomodulator and protein phosphatase 2A (PP2A)-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven myeloproliferative neoplasms.

  2013cites this paper
• JAK2V617F-positive Myeloproliferative Neoplasms : KI mouse models, Interferon-α therapy and clonal architecture

  2013cites this paper
• The Mevalonate Pathway: A Potential Therapeutic Target for JAK2-driven Myeloproliferative Neoplasms

  2013influential citation
• Molecular analysis of the Drosophila JAK/STAT pathway receptor complex

  2013cites this paper
• On the Regulation and Activation of JAK2: A Novel Hypothetical Model

  2013cites this paper
• Lipocalin‐2 is associated with modulation of disease phenotype in a patient with concurrent JAK2‐V617F and BCR‐ABL mutation

  2012cites this paper
• Comparison of mutated JAK2 and ABL1 as oncogenes and drug targets in myeloproliferative disorders

  2012cites this paper
• Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

  2012cites this paper
• Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia

  2012cites this paper
• Disordered signaling in myeloproliferative neoplasms.

  2012influential citation
• Regulation of JAKs: Insights gleaned from the functional protein domains

  2012cites this paper
• Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation.

  2012cites this paper
• Title Comparison of mutated JAK 2 and ABL 1 as oncogenes and drug targets in myeloproliferative disorders

  2012cites this paper